Sarcopenia Market

1. Sarcopenia Market Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases. DelveInsight's "Sarcopenia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Sarcopenia , historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Geography Covered    The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period:2017-2030 Sarcopenia Epidemiology Current definitions of sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80. The Sarcopenia epidemiology division provide insights about historical and current Sarcopenia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

2. Sarcopenia Drug Chapters Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials. Some of the potential candidates are elaborated below. Drug chapter segment of the Sarcopenia report encloses the detailed analysis of Sarcopenia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sarcopenia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Sarcopenia Market Outlook Early recognition and intervention is the key to improved outcomes in patients with sarcopenia. Screening patients for impairment in their physical function and activities of daily living (ADLs) should be a routine part of healthcare visits for the elderly. Currently, there are no agents for the treatment of sarcopenia that have been FDA approved. Nutritional supplementation, resistance training, exercise, vibrational therapy constitute the treatment space for sarcopenia. Compared with singular interventions, combined interventions, including comprehensive exercise‐based treatment interventions, such as resistance training and nutritional intervention, are effective for improving sarcopenia and are recommended. The Sarcopenia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Sarcopenia markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Sarcopenia market in 7MM is expected to change in the study period 2017- 2030.